Anatomy Of The Avandia Decision: FDA’s Woodcock Splits The Difference Between OND, OSE Views
In deciding to keep GlaxoSmithKline PLC’s Avandia on the market, while also heavily restricting its use, FDA Center for Drug Evaluation and Research Director Janet Woodcock split the difference between opposing recommendations from the Office of New Drugs and Office of Surveillance and Epidemiology.
More from Archive
More from Pink Sheet
• By
Brazil’s drug regulator has published a new technical note updating guidelines on registration and post-registration procedures for biological products.
• By
Nirogacestat was one of four products scheduled for an oral explanation meeting at the European Medicines Agency this week.
• By
Three weeks after its user fee goal date, the FDA demanded a postmarketing commitment “to generate additional data,” Novavax said.